Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Hellmich

Showing results (361-370 of 390) with videos related to

Pageof 39
Sort By:
Schizophrenia Bulletin|April 6, 2023
Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT)Andreas Bechdolf, Hendrik Müller, Martin Hellmich, et al.
JAMA Network Open|May 29, 2020
Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical TrialFranziska Maier, Annika Spottke, Jan-Philipp Bach, et al.
European Journal of Heart Failure|August 26, 2025
Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trialMarkus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
BMJ Open|January 26, 2022
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocolHeidrun Golla, Kim Dillen, Martin Hellmich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Circulation|April 12, 2024
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management EraFelix Gerhardt, Eva Fiessler, Karen M Olsson, et al.
Circulation|February 12, 2025
MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled TrialSimon Braumann, Sascha Macherey-Meyer, Amin Polzin, et al.
European Journal of Heart Failure|August 30, 2024
Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathySimon Geissen, Simon Braumann, Joana Adler, et al.
Trials|November 13, 2024
PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trialRouvier Al-Monajjed, Peter Albers, Johanna Droop, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 2, 2023
Apathy in patients with Alzheimer's disease is a cost-driving factorChristopher Kruse, Franziska Maier, Annika Spottke, et al.
Pageof 39

Showing results (361-370 of 390) with videos related to

Sort By:
Pageof 39
Schizophrenia Bulletin|April 6, 2023
Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT)Andreas Bechdolf, Hendrik Müller, Martin Hellmich, et al.
JAMA Network Open|May 29, 2020
Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical TrialFranziska Maier, Annika Spottke, Jan-Philipp Bach, et al.
European Journal of Heart Failure|August 26, 2025
Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trialMarkus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
BMJ Open|January 26, 2022
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocolHeidrun Golla, Kim Dillen, Martin Hellmich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Circulation|April 12, 2024
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management EraFelix Gerhardt, Eva Fiessler, Karen M Olsson, et al.
Circulation|February 12, 2025
MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled TrialSimon Braumann, Sascha Macherey-Meyer, Amin Polzin, et al.
European Journal of Heart Failure|August 30, 2024
Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathySimon Geissen, Simon Braumann, Joana Adler, et al.
Trials|November 13, 2024
PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trialRouvier Al-Monajjed, Peter Albers, Johanna Droop, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 2, 2023
Apathy in patients with Alzheimer's disease is a cost-driving factorChristopher Kruse, Franziska Maier, Annika Spottke, et al.
Pageof 39